- Headquarters
- Basel, Switzerland · Europe
- Value chain
- Medicines & vaccines(Products)
- What that means
- Develops and sells therapeutics under its own name: drugs, biologics, vaccines, cell and gene therapies and radiopharmaceuticals.
- Founded
- 1996
- Staff
- 76,000 (2024)
- Ownership
- Listed
- Listing
- SIX:NOVN on Google Finance
- Website
- novartis.com
- Relevance
- Very high at its strongest, in Nuclear Medicine & Radioisotope Technologies
Basel, SwitzerlandIn 2 capabilities
Each capability the company is listed in, most relevant first: how experts in the field see its global relevance there, why it is listed and the source.
Biotechnology & Health Technologies · Design · listed #3 of 50
Global leader in radioligand therapy with Lutathera and Pluvicto (Lu-177), produced by its Advanced Accelerator Applications unit across dedicated radiopharmaceutical plants.
Relevance: Global leader in radioligand therapy
Biotechnology & Health Technologies · Design · listed #9 of 50
Pioneer of new modalities: Kymriah CAR-T, Zolgensma gene therapy, Leqvio siRNA and Pluvicto radioligand therapy.
Relevance: Pioneer of CAR-T, gene and siRNA therapies